SCHEMBL5741014

SCHEMBL5741014

Fc1ccc(-c2ccc(-n3ncc(CN4CCOCC4)c3-c3ccccc3F)cn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 1/20 0.43
ALOX5AP P20292 3/20 0.42
FEN1 P39748 3/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
JAK2 O60674 2/20 0.41
JAK1 P23458 2/20 0.41
TYK2 P29597 2/20 0.41
JAK3 P52333 2/20 0.41
MCHR1 Q99705 1/20 0.40
KCNH2 Q12809 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MAPK13 O15264 2/20 0.36
MAPK12 P53778 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5907275 0.94 CYP2A13 (0.44) CYP2A13ALOX5APFEN1ADORA2AADORA1
SCHEMBL7262216 0.89 HTR2C (0.40) JAK2JAK1TYK2JAK3MCHR1
SCHEMBL5907238 0.86 CYP2A13 (0.50) CYP2A13ALOX5APFEN1ADORA2AADORA1
SCHEMBL5907245 0.85 CYP2A13 (0.44) CYP2A13ALOX5APFEN1ADORA2AADORA1
SCHEMBL5907378 0.84 ALDH1A1 (0.42) ADORA2AADORA1ALDH1A1L3MBTL1DRD2
SCHEMBL5907286 0.84 CYP2A13 (0.44) CYP2A13ALOX5APFEN1ADORA2AADORA1
SCHEMBL5730793 0.83 CYP2A13 (0.45) CYP2A13ALOX5APFEN1ADORA2AADORA1
SCHEMBL5907335 0.83 CYP2A13 (0.47) CYP2A13ALOX5APFEN1ADORA2AADORA1
SCHEMBL5907291 0.83 MAP4K1 (0.41) ADORA2AADORA1JAK2JAK1TYK2
SCHEMBL5907388 0.83 SSTR5 (0.37) ALOX5APFEN1ALDH1A1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264419-A1 Substituted pyrazoles MERCK PATENT GMBH (DE) 2006-11-23 US disclosed
CN-1768051-A Substituted pyrazoles MERCK PATENT GMBH (DE) 2006-05-03 CN disclosed
EP-1626967-A1 SUBSTITUTED PYRAZOLES MERCK PATENT GmbH (DE) 2006-02-22 EP disclosed
WO-2004089931-A1 SUBSTITUTED PYRAZOLES MERCK PATENT GMBH (DE) 2004-10-21 WO disclosed
WO-2003031435-A1 PYRAZOLE DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS MERCK PATENT GMBH (DE) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264419-A1 Substituted pyrazoles HTR3A, HTR1A, HTR1D CYP2A13 659/4885ALOX5AP 2479/4885FEN1 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.